Abstract:Objectives To evaluate prospectively the efficacy of Extracorporeal Shock Wave Therapy (ESWT) as a conservative treatment for Peyronie's disease. Methods 112 patients from January 2022 to January 2023 were included in the prospective study. Each patient was treated with a minimum of three sessions of ESWT (3000 shock wavs at an energy density of 0.11-0.17 mJ/mm2) at 3-week intervals. The angulation was calculated by auto-photography: the mean angulation before treatment was 48 degrees (range 10°-100°). The severity of pain on erection was assessed by a visual analog scale (0-5): all patients had symptoms (60 scored 5). Moreover a self-evaluation questionnaire (International Index of Erectile Function) was used: 42 patients had erectile dysfunction (IIEF<18). The plaque was located by palpation. The mean disease duration was 18 months (4-60 mo). The mean follow up was 9 months (4-24). Results All patients completed the protocol. The tolerance and safety were excellent. The results were analysed using the Wilcoxon signed-rank test. Of the 60 patients with pain on erection, 54 (90%) noticed immediately relief after ESWT with mean reduction 2.9 on the visual analog pain scale (p<0.00001). An improvement in angulation greater than 10 degrees was observed in 64 patients (57.1%), with a mean reduction of 30 degrees (p<0.001). 11 patients with erectile dysfunction (26.2%) han an increased IIEF score greater than 4. 62 patients (55.4%) thought the plaque was smoother. Only 2 patients (1.8%) experimented minimal bruising at the site of treatment the day after, no major complications were reported. Conclusions ESWT represents an effective, feasable and safe conservative treatment for Peyronie's disease. It seems to reduce pain during erection and sometimes improve the penile angle. Long-term follow up and further results are required. Conflicts of Interest No.

(388) Extracorporeal Shock Wave Therapy (Eswt) In The Treatment Of Peyronie'S Disease: Our Initial Experience